scholarly journals Endoscopic Mucosal Healing as a Treatment Target in Ulcerative Colitis: Does It Have the Same Role in Asian Patients?

Gut and Liver ◽  
2021 ◽  
Author(s):  
Suk-Kyun Yang ◽  
Sang Hyoung Park ◽  
Byong Duk Ye
Keyword(s):  
Ulcerative Colitis ◽  
Mucosal Healing ◽  
Treatment Target ◽  
Asian Patients

scholarly journals P063 Faecal calprotectin as a non-invasive treatment target to predict mucosal healing and histological remission in asymptomatic ulcerative colitis

2018 ◽  
Vol 12 (supplement_1) ◽  
pp. S124-S125
Author(s):  
A Correia Varela Almeida ◽  
J M Vázquez Morón ◽  
E Gómez Delgado ◽  
H Pallarés Manrique ◽  
A Talavera Fabuel ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Mucosal Healing ◽  
Invasive Treatment ◽  
Faecal Calprotectin ◽  
Treatment Target ◽  
Non Invasive ◽  
Histological Remission

Overview of Biological Therapy in Ulcerative Colitis: Current and Future Directions

2015 ◽  
Vol 24 (2) ◽  
pp. 203-213 ◽  
Author(s):  
Federica Furfaro ◽  
Cristina Bezzio ◽  
Sandro Ardizzone ◽  
Alessandro Massari ◽  
Roberto De Franchis ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Immunosuppressive Agents ◽  
Mucosal Healing ◽  
Aminosalicylic Acid ◽  
Proinflammatory Mediators ◽  
Experimental Drugs ◽  
New Treatments ◽  
Aggressive Clinical Course ◽  
Near Future

The treatment of ulcerative colitis (UC) has changed over the last decade. It is extremely important to optimize the therapies which are available nowadays and commonly used in daily clinical practice, as well as to stimulate the search for more powerful drugs for the induction and maintenance of sustained and durable remission, thus preventing further complications. Therefore, it is mandatory to identify the patients' prognostic variables associated with an aggressive clinical course and to test the most potent therapies accordingly.To date, the conventional therapeutic approach based on corticosteroids, salicylates (sulfasalazine, 5-aminosalicylic acid) or immunosuppressive agents is commonly used as a first step to induce and to maintain remission. However, in recent years, knowledge of new pathogenetic mechanisms of ulcerative colitis have allowed us to find new therapeutic targets leading to the development of new treatments that directly target proinflammatory mediators, such as TNF-alpha, cytokines, membrane migration agents, cellular therapies.The aim of this review is to provide the most significant data regarding the therapeutic role of drugs in UC and to give an overview of biological and experimental drugs that will become available in the near future. In particular, we will analyse the role of these drugs in the treatment of acute flare and maintenance of UC, as well as its importance in mucosal healing and in treating patients at a high risk of relapse.

scholarly journals Effect of disease duration on the association between serum albumin and mucosal healing in patients with ulcerative colitis

2021 ◽  
Vol 8 (1) ◽  
pp. e000662
Author(s):  
Sen Yagi ◽  
Shinya Furukawa ◽  
Kana Shiraishi ◽  
Yu Hashimoto ◽  
Kazuhiro Tange ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Serum Albumin ◽  
Clinical Outcomes ◽  
Clinical Remission ◽  
Acute Inflammation ◽  
Japanese Patients ◽  
Cross Sectional Study ◽  
Mucosal Healing ◽  
High Serum ◽  
Cross Sectional

ObjectiveSerum albumin is used as a marker of acute inflammation. Several studies have addressed the association between serum albumin and clinical outcome in patients with ulcerative colitis (UC). While mucosal healing (MH) has been indicated as the therapeutic goal for UC, the association between serum albumin and MH remains unclear. We evaluated this issue in patients with UC overall and explored whether duration of UC affected this association.DesignThis cross-sectional study recruited consecutive patients with UC. Study subjects consisted of 273 Japanese patients with UC. Serum albumin was divided into tertiles based on its distribution in all study subjects. One endoscopy specialist was responsible for measuring partial MH and MH, which were defined as a Mayo endoscopic subscore of 0–1 and 0, respectively. The association between serum albumin and clinical outcomes was assessed by multivariate logistic regression.ResultsRates of clinical remission, partial MH and MH were 57.9%, 63% and 26%, respectively. Only high serum albumin (>4.4 mg/dL) was significantly positively associated with MH (OR 2.29 (95% CI: 1.03 to 5.29), p for trend=0.043). In patients with short UC duration (<7 years) only, high serum albumin was significantly positively associated with MH and clinical remission. In patients with long UC duration (≥7 years), in contrast, no association between serum albumin and clinical outcomes was found.ConclusionIn Japanese patients with UC, serum albumin was significantly positively associated with MH. In patients with short UC duration, serum albumin might be a useful complementary marker for MH.

scholarly journals Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Kaoru Yokoyama ◽  
Kiyonori Kobayashi ◽  
Miyuki Mukae ◽  
Miwa Sada ◽  
Wasaburo Koizumi
Keyword(s):  
Ulcerative Colitis ◽  
Clinical Study ◽  
Mucosal Healing ◽  
Long Term Outcomes

Mucosal Healing in Ulcerative Colitis: Where do we Stand?

2011 ◽  
Vol 12 (10) ◽  
pp. 1417-1423 ◽  
Author(s):  
Gionata Fiorino ◽  
Monica Cesarini ◽  
Amedeo Indriolo ◽  
Alberto Malesci
Keyword(s):  
Ulcerative Colitis ◽  
Mucosal Healing

scholarly journals Association Between Platelet Count and Mucosal Healing in Japanese Patients With Ulcerative Colitis: Cross-Sectional Study

2020 ◽  
Author(s):  
Shinya Furukawa ◽  
Sen Yagi ◽  
Kana Shiraishi ◽  
Kenichirou Mori ◽  
Tomoyuki Ninomiya ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Platelet Count ◽  
Japanese Patients ◽  
Cross Sectional Study ◽  
Mucosal Healing ◽  
Confounding Factors ◽  
Cross Sectional ◽  
Factor Α ◽  
Very High ◽  
Necrosis Factor

Abstract Background: Mucosal healing (MH) has been indicated as the therapeutic goal for ulcerative colitis (UC). Platelet count is known as an inflammation evaluation. However, the association between platelet count and MH among patients with UC is still scarce. We therefore assessed this issue among Japanese patients with UC.Methods: The study subjects consisted of 345 Japanese patients with UC. Platelet count was divided into quartiles on the basis of the distribution of all study subjects (low, moderate, high, and very high). Several endoscope specialists were responsible for evaluating MH and partial MH, which was defined as a Mayo endoscopic subscore of 0 and 0-1, respectively. Estimations of crude odds ratios (ORs) and their 95% confidence intervals (CIs) for partial MH and MH in relation to platelet count were performed using logistic regression analysis. Age, sex, CRP, steroid use, and anti-Tumor necrosis factor α (TNFα) preparation were selected a priori as potential confounding factors.Results: The percentage of partial MH and MH were 63.2 and 26.1%, respectively. Moderate and very high was independently inversely associated with partial MH (moderate: OR 0.40 [95%CI: 0.19-0.810], very high: OR 0.37 [95%CI: 0.17-0.77], p for trend= 0.034). Similarly, moderate, high, and very high were independently inversely associated with MH (moderate: OR 0.37 [95% CI: 0.18-0.73], high: OR 0.41 [95% CI: 0.19-0.83], and very high: OR 0.45 [95% CI: 0.21-0.94], p for trend = 0.033) after adjustment for confounding factors.Conclusions: Among patients with UC, platelet count was independently inversely associated with MH.

Sign in / Sign up

Export Citation Format

Share Document